Navigation Links
Protege Encore Clinical Trial Evaluates New Investigational Approach For Individuals Recently Diagnosed With Type 1 Diabetes
Date:5/10/2010

WELLINGTON, Fla., May 10 /PRNewswire-USNewswire/ -- Dr. Richard Hays announced today that he is now recruiting children with newly diagnosed type 1 diabetes for Protege Encore, a randomized, placebo-controlled Phase III clinical trial. This is the second of two Phase III studies testing the safety and efficacy of an investigational drug called teplizumab. The first study, known as Protege, has completed enrollment of more than 530 subjects with type 1 diabetes. There is currently no approved therapy to slow the progression of type 1 diabetes.

In patients with type 1 diabetes, T cells of the immune system attack and destroy beta cells that are located in the pancreas and make insulin. Teplizumab works by binding to CD3 receptors on the surface of the T cells and, by doing so, may modulate the autoimmune attack on pancreatic beta cells and preserve or protect these cells. If effective, patients may require less injected insulin and their blood glucose levels may be easier to control.

In an earlier trial of teplizumab, a small group of subjects with diabetes of recent onset were noted to have improved function of their beta cells, improved glucose control, and reduced insulin requirements for up to two years. These findings are being further studied in the Protege and Protege Encore clinical trials.

The Protege Encore trial is designed to determine if teplizumab can preserve pancreatic insulin production, which may make diabetes easier to manage. "We have a lot of enthusiasm about the teplizumab studies and their implications. It is hoped that one day we can offer a new treatment option to help patients better manage their disease," Dr. Hays commented.

Approximately 125 study sites across 16 countries will be enrolling 400
'/>"/>

SOURCE Richard M. Hays, M.D., P.A.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. MacroGenics and Lilly Achieve Targeted Patient Enrollment in PROTEGE, a Global Phase 2/3 Clinical Trial of Teplizumab in Type 1 Diabetes
2. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
3. Novocell Becomes ViaCyte, Inc., as it Accelerates Pre-Clinical Development of a Stem Cell Derived Treatment for Diabetes
4. Stereotaxis Updates Progress on Major Clinical Initiative Related to Electrophysiology (EP) Treatment of Ventricular Tachycardia
5. US HIFU Receives Unanimous Approval to Continue the Clinical Investigation of High Intensity Focused Ultrasound (HIFU) for Treatment of Prostate Cancer
6. Lexicon to Provide Clinical Pipeline Update and Report First Quarter 2010 Financial Results
7. Omeros Reports Additional Phase 2 Data Showing Multiple Clinical Benefits In Patients Undergoing Meniscectomy Surgery
8. US Oncology Meets With Leading Pharmaceutical and Biotech Companies to Design Clinical Trials for the Cancer Fighting Drugs of Tomorrow
9. OrbusNeichs Genous(TM) Bio-engineered R stent(TM) Demonstrates Excellent Safety and Clinical Outcomes in High-Risk Elderly Patients
10. Lotus Pharmaceuticals Laevo-Bambuterol Received SFDA Approval to Commence Clinical Trials
11. Novavaxs Seasonal Influenza VLP Vaccine Candidate Shows Positive Results in a Phase II Clinical Trial in Older Adults
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2015)... Sept. 3, 2015 Report ... New Drugs, Industry Changes and Emerging Opportunities What,s ... ovaries? Visiongain,s new study forecasts those pharmaceutical revenues. ... that industry. You also explore trends, results, treatments, ... report gives revenue predictions to 2025 at overall ...
(Date:9/3/2015)... About self-monitoring blood glucose device ... device. It consists of a glucose sensor and ... through radiowaves from the sensor to a receiver, ... self-monitoring blood glucose devices can improve self-management of ... diabetes treatment. Technavio,s analysts forecast the ...
(Date:9/3/2015)... Nevro Corp. (NYSE: NVRO ), a ... solutions for the treatment of chronic pain, today announced ... Stanley Global Healthcare Conference on Thursday, September 17, 2015 ... is scheduled to present at 11:45 a.m. ET.  The ... accessible in the "Investors" section of the company,s website ...
Breaking Medicine Technology:Ovarian Cancer Drug Therapy: Companies, R&D and Revenue Forecasts 2015-2025: Recently Approved Treatments Give High Market Potential 2Ovarian Cancer Drug Therapy: Companies, R&D and Revenue Forecasts 2015-2025: Recently Approved Treatments Give High Market Potential 3Ovarian Cancer Drug Therapy: Companies, R&D and Revenue Forecasts 2015-2025: Recently Approved Treatments Give High Market Potential 4Ovarian Cancer Drug Therapy: Companies, R&D and Revenue Forecasts 2015-2025: Recently Approved Treatments Give High Market Potential 5Ovarian Cancer Drug Therapy: Companies, R&D and Revenue Forecasts 2015-2025: Recently Approved Treatments Give High Market Potential 6Global Self-monitoring Blood Glucose Devices Market 2015-2019 2
... March 2, 2012  ZONARE Medical Systems, Inc., a leading ... results for the fourth quarter and fiscal year ended ... $70 million, resulting in 20% year-over-year sales growth. Sales ... company reported an operating profit for the quarter. More ...
...  Medical Science Liaisons (MSLs) have become a key link between ... leaders that drive marketplace success. And the role of MSLs ... in the coming years as the device industry turns to ... Given the expanding role of MSLs, it,s critical for ...
Cached Medicine Technology:ZONARE Reports Fourth Quarter and 2011 Results 2New Study Examines the Evolving Role of Medical Science Liaisons in the Medical Device Sector 2
(Date:9/3/2015)... (PRWEB) , ... September 03, 2015 , ... ... he made the company the final destination of his six-month, 10,000 mile journey ... , During the trek—which he calls the “Connecting Las Americas” project—Max crossed ...
(Date:9/3/2015)... , ... September 03, 2015 , ... ... Leadership® and Navigant Center for Healthcare Research and Policy Analysis has found physician ... , While 47 percent of respondents said their organizations conduct some ...
(Date:9/3/2015)... , ... September 03, 2015 , ... ... Scholarship applications are open for spring 2016. Scholarships are awarded two times each ... For The Warriors® is a national nonprofit dedicated to restoring a sense of ...
(Date:9/3/2015)... ... September 03, 2015 , ... Today, ... Management Suite customers, as part of the LANDESK One Partner program. ... delivering the best mobile user experience in remote access and control:, ...
(Date:9/3/2015)... ... 03, 2015 , ... The first part of a two-part investigative news segment ... filter lawsuits filed against Bard.** These lawsuits, filed by persons and the family ... or failed, have recently been consolidated for pretrial proceedings as multidistrict litigation, MDL 2641 ...
Breaking Medicine News(10 mins):Health News:Topical BioMedics Announces Visit from Max Wohlgemuth Kitslaar, Ending his Six-Month, 10,000 Mile Journey from Chile to New York on a 1976 Moto Guzzi Motorcycle 2Health News:Topical BioMedics Announces Visit from Max Wohlgemuth Kitslaar, Ending his Six-Month, 10,000 Mile Journey from Chile to New York on a 1976 Moto Guzzi Motorcycle 3Health News:Topical BioMedics Announces Visit from Max Wohlgemuth Kitslaar, Ending his Six-Month, 10,000 Mile Journey from Chile to New York on a 1976 Moto Guzzi Motorcycle 4Health News:Topical BioMedics Announces Visit from Max Wohlgemuth Kitslaar, Ending his Six-Month, 10,000 Mile Journey from Chile to New York on a 1976 Moto Guzzi Motorcycle 5Health News:Topical BioMedics Announces Visit from Max Wohlgemuth Kitslaar, Ending his Six-Month, 10,000 Mile Journey from Chile to New York on a 1976 Moto Guzzi Motorcycle 6Health News:Survey finds growing movement for physician leadership training 2Health News:Survey finds growing movement for physician leadership training 3Health News:Hope For The Warriors Spouse/Caregiver Scholarships Now Open for Spring 2016 2Health News:Splashtop Partners with LANDESK to Deliver High Performance Remote Access and Remote Support to and from Mobile Devices and Chromebook 2Health News:Splashtop Partners with LANDESK to Deliver High Performance Remote Access and Remote Support to and from Mobile Devices and Chromebook 3Health News:Splashtop Partners with LANDESK to Deliver High Performance Remote Access and Remote Support to and from Mobile Devices and Chromebook 4Health News:Bard IVC Lawsuit Allegations Reach National Prime Time News 2Health News:Bard IVC Lawsuit Allegations Reach National Prime Time News 3
... results by a Swedish doctor involving more than 65, 000 ... sugar and the risk of developing cancer//. , Dr. Par ... data from 31,304 men and 33,293 women, led the research. ... and had glucose (blood sugar) measurements available. In total 2,478 cases ...
... higher body mass index (BMI) tend are less likely to ... , according to a report. ,An ischemic stroke ... the brain is blocked or reduced and sufficient amounts of ... weight are risk factors for stroke and may influence outcome ...
... School Dr. Aaron Lazare has decided to step down due ... cardiac arrhythmia. ,Dr. Lazare was responsible for the ... He has also set up the $ 100 million research ... of psychiatry and chair of the department after serving 14 ...
... TB burden, with about 40 per cent of the country's population// ... million people in India develop TB and 4,50,000 die from it, ... India than other infectious diseases, it has been reported. ... children under the age of 14 years. They are exposed to ...
... Scotland’s top golfer Colin Montgomerie says he will ‘do ... Roy Castle Lung Cancer Foundation//, to build a world-class specialty ... , The building will be named the Elizabeth ... from the disease in 1991.Montgomerie was very close to his ...
... by a specialist headache centre, it was observed that eight ... at work; 91 per cent blamed the ineffectiveness to headaches, ... published in the March issue of Cephalalgia. ,"Migraines ... when they are often at their most productive, so the ...
Cached Medicine News:Health News:Beware of High Sugar Levels Even If You are Not Diabetic 2Health News:Stroke Patients With High BMI Less Likely to Be Discharged After Hospitalization 2Health News:TB Incidence on Rise Among Children in Tamil Nadu, Maharashtra 2Health News:Golfer Plans ‘lasting Legacy’ for Moth 2Health News:Work Absence Due to Headaches Has a Substantial Socio-economic Effect 2
Single-action, stainless steel micro biopsy forceps....
The Optima III 45 cm line of laparoscopic hand instruments is ideal for operative laparoscopic/endoscopic procedures or when a longer instrument is needed....
The Snap-In Snap-Out-II Tip Inserts offer a large variety of configurations....
The Snap-In Snap-Out-II Tip Inserts offer a large variety of configurations....
Medicine Products: